346 completed, 106 terminated, 53 recruiting, 45 unknown. 248 Phase 1, 237 Phase 2, 67 Not applicable, 41 Phase 3, 10 Phase 4.
Follow Lymphoma, T-Cell, Cutaneous: new trials by email Literature Review of Lymphoma, T-Cell, Cutaneous trials Research Report on Lymphoma, T-Cell, Cutaneous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FLASH Pilot Phase 1 Safety Study IntraOp Mobetron UHDR, Linac - Cutaneous Lymphoma | Not applicable | Not yet recruiting | Lesley A. Jarvis | 10 | 2029-10-31 | 2026-05-27 |
| Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution APR-TD011 (RLF-TD011) - Cutaneous T Cell Lymphoma | Early Phase 1 | Not yet recruiting | Northwestern University | 30 | 2027-01-01 | 2026-05-01 |
| A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides Duvelisib - Mycosis Fungoides, Cutaneous T-cell Lymphoma | Phase 1 | Not yet recruiting | SecuraBio | 30 | 2027-01-01 | 2026-07-20 |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma Zeprumetostat Tablets - Cutaneous T-Cell Lymphoma/Mycosis Fungoides/Sézary Syndrome | Phase 2 | Not yet recruiting | Peking University First Hospital | 33 | 2026-10-31 | 2026-10-02 |
| Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Washington University School of Medicine | 24 | 2026-09-30 | 2026-07-06 |
| A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma KK2223 - T-cell NHL (PTCL or CTCL) | Phase 1 | Recruiting | Kyowa Kirin, Inc. | 72 | 2026-09-02 | 2026-09-30 |
| Topical JAK-Inhibition of Early-Stage CTCL delgocitinib - Mycosis Fungoides, Cutaneous T-cell Lymphoma | Phase 2 | Not yet recruiting | Aarhus University Hospital | 15 | 2026-09-01 | 2026-08-26 |
| Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) Brentuximab Vedotin (Bv), Lisaftoclax (APG-2575) - Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Not yet recruiting | Peking University First Hospital | 46 | 2026-07-31 | 2026-07-23 |
| A Study of VG712 in Patients With Mycosis Fungoides VG712, Mogamulizumab - Mycosis Fungoides | Phase 2 | Not yet recruiting | Virogen Biotechnology Inc. | 386 | 2026-07-30 | 2026-04-14 |
| Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell Lymphoma Benvitimod Cream, Placebo cream - Cutaneous T-Cell Lymphoma, Mycosis Fungoides (MF) | Phase 2 | Not yet recruiting | Peking University First Hospital | 35 | 2026-07-01 | 2026-06-22 |
| Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica. Lymph Node Cancer, Cutaneous | Not yet recruiting | Caja Costarricense de Seguro Social | 350 | 2026-05-01 | 2026-04-20 | |
| Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides A-dmDT390-bisFv(UCHT1), Vorinostat - Mycosis Fungoides | Phase 2 | Withdrawn | Virogen Biotechnology Inc. | 2026-05-01 | 2026-05-18 | |
| Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD) blood sampling - Sezary Syndrome, Ichthyosis, Lamellar | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 10 | 2026-04-01 | 2026-03-17 | |
| Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma Aclarubicin, Cyclophosphamide, Vincristine - Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 37 | 2026-03-30 | 2026-04-17 |
| Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease | Phase 2 | Recruiting | Jonathan Brammer | 44 | 2026-02-12 | 2026-04-15 |
| A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies INCA036873 - Solid Tumors, Hematologic Malignancies | Phase 1 | Recruiting | Incyte Corporation | 280 | 2026-01-08 | 2026-10-09 |
| A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL) DT-7012 - Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides | Early Phase 1 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-01-01 | 2025-10-09 |
| Amping up With PemJAK Ruxolitinib, Pembrolizumab - Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma | Phase 2 | Recruiting | Seda S. Tolu | 53 | 2025-12-03 | 2025-12-16 |
| Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance Brentuximab Vedotin (Bv), Placebo - Cutaneous T Cell Lymphoma (CTCL), Brentuximab Vedotin | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 84 | 2025-11-01 | 2025-09-17 |
Showing 20 of 633. Sign in to see all of them.
Mycosis Fungoides (444) · Sezary Syndrome (365) · Leukemia, Lymphocytic, Chronic, B-Cell (290) · Lymphoma, Non-Hodgkin (289) · Lymphoma, Follicular (286) · Lymphoma, Large B-Cell, Diffuse (285) · Lymphoma, B-Cell, Marginal Zone (279) · Lymphoma, Mantle-Cell (274) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (272) · Hodgkin Disease (265) · Burkitt Lymphoma (263) · Lymphoma, Large-Cell, Immunoblastic (251) · Lymphoma (246) · Lymphoma, Large-Cell, Anaplastic (215)
Hemic and Lymphatic Diseases (633) · Neoplasms by Histologic Type (633) · Immunoproliferative Disorders (630) · Lymphatic Diseases (630) · Immune System Diseases (629) · Lymphoproliferative Disorders (597) · Neoplasms (583) · Lymphoma, T-Cell (577) · Lymphoma (387) · Lymphoma, Non-Hodgkin (344) · Hematologic Diseases (333) · Leukemia, Lymphoid (326) · Pathological Conditions, Signs and Symptoms (322) · Pathologic Processes (316) · Disease Attributes (313)
Cyclophosphamide (48) · fludarabine phosphate (45) · Peripheral Blood Stem Cell Transplantation (44) · Mycophenolic Acid (33) · Cyclosporine (29) · Whole-Body Irradiation (29) · Busulfan (26) · Antilymphocyte Serum (24) · Tacrolimus (24) · Etoposide (21) · Methotrexate (21) · Filgrastim (20) · Radiotherapy (20) · romidepsin (20) · Brentuximab Vedotin (18)
National Cancer Institute (NCI) (66) · Fred Hutchinson Cancer Center (34) · Northwestern University (23) · City of Hope Medical Center (22) · Mayo Clinic (20) · M.D. Anderson Cancer Center (18) · Memorial Sloan Kettering Cancer Center (17) · Case Comprehensive Cancer Center (14) · European Organisation for Research and Treatment of Cancer - EORTC (14) · National Institutes of Health Clinical Center (CC) (12) · Assistance Publique - Hôpitaux de Paris (10) · Jonsson Comprehensive Cancer Center (9) · Roswell Park Cancer Institute (9) · Stanford University (9) · Vanderbilt-Ingram Cancer Center (9)
United States (491) · France (41) · Italy (37) · Germany (32) · United Kingdom (28) · Spain (25) · Canada (23) · Switzerland (22) · Australia (19) · China (17) · Belgium (16) · Austria (13) · Netherlands (11) · Japan (9) · Poland (9)
Timothy M. Kuzel, MD (6) · Brenda Sandmaier (4) · David Maloney (4) · Madeleine Duvic, MD (4) · Roger Strair, MD, PhD (4) · Shivaani Kummar, MD (4) · Thomas E. Witzig, MD (4) · Ajay Gopal (3) · Barbara Pro, MD (3) · David G. Savage, MD (3) · David J. Straus, MD (3) · Diana M. Escolar, MD, FAAN (3) · Joan Guitart, MD (3) · John A. Glaspy, MD, MPH (3) · Kyoo H. Lee, MD (3)
PMID 32632956, PMID 32499241, PMID 33883258, PMID 22045986, PMID 23069814, PMID 23770157, PMID 25795722, PMID 28600132, PMID 32508818, PMID 33072126, PMID 34091453, PMID 35175355, PMID 35536441, PMID 39821757, PMID 10552943, PMID 10764422, PMID 11231324, PMID 11410496, PMID 11675364, PMID 11895901, PMID 1244564, PMID 12525530, PMID 12543862, PMID 12588222, PMID 12873880, PMID 14630685, PMID 15013589, PMID 15107815, PMID 15459300, PMID 16135477, PMID 16148284, PMID 16710026, PMID 16731764, PMID 17020988, PMID 17119113, PMID 17366595, PMID 17397698, PMID 17515522, PMID 17515574, PMID 17854367, PMID 18079362, PMID 18293016, PMID 18327587, PMID 18463792, PMID 18596230, PMID 18645136, PMID 18698002, PMID 19170225, PMID 19199905, PMID 19451403
P30CA015704 (15), P30CA033572 (15), P30CA043703 (11), P30CA015083 (10), P30CA068485 (7), P30CA072720 (7), P30CA016672 (6), P01CA018029 (5), P30CA022453 (5), U01CA062502 (5), 2018 (4), P30CA016058 (4), P30CA016086 (4), P30CA060553 (4), U01CA062491 (4)